[{"orgOrder":0,"company":"University Hospital, Rouen","sponsor":"Laboratoire Dielen","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Amino Acid","year":"2025","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1; Amidophosphoribosyltransferase; Glutamine synthetase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"University Hospital, Rouen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Rouen \/ Laboratoire Dielen","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Rouen \/ Laboratoire Dielen"},{"orgOrder":0,"company":"Insel Gruppe AG, University Hospital Bern","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1; Amidophosphoribosyltransferase; Glutamine synthetase","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Insel Gruppe AG, University Hospital Bern","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insel Gruppe AG, University Hospital Bern \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"11","companyTruncated":"Insel Gruppe AG, University Hospital Bern \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Amino Acid","year":"2010","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1; Amidophosphoribosyltransferase; Glutamine synthetase","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Istanbul University","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"TURKEY","productType":"Amino Acid","year":"2017","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1; Amidophosphoribosyltransferase; Glutamine synthetase","graph1":"Urology","graph2":"Undisclosed","graph3":"Istanbul University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Istanbul University \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"1","companyTruncated":"Istanbul University \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Children's Hospital Medical Center, Cincinnati","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases | Emmaus Life Sciences | University of Michigan | Gabrail Cancer Center Research | University of Colorado, Denver","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1; Amidophosphoribosyltransferase; Glutamine synthetase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Children's Hospital Medical Center, Cincinnati","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital Medical Center, Cincinnati \/ National Institute of Diabetes and Digestive and Kidney Diseases | Emmaus Life Sciences | University of Michigan | Gabrail Cancer Center Research | University of Colorado, Denver","highestDevelopmentStatusID":"1","companyTruncated":"Children's Hospital Medical Center, Cincinnati \/ National Institute of Diabetes and Digestive and Kidney Diseases | Emmaus Life Sciences | University of Michigan | Gabrail Cancer Center Research | University of Colorado, Denver"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Emmaus Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Amino Acid","year":"2010","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1; Amidophosphoribosyltransferase; Glutamine synthetase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Gabrail Cancer Center Research \/ Emmaus Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Gabrail Cancer Center Research \/ Emmaus Life Sciences"},{"orgOrder":0,"company":"Hawaii Pacific Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Amino Acid","year":"2019","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Endocrinology","graph2":"Phase I","graph3":"Hawaii Pacific Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hawaii Pacific Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hawaii Pacific Health \/ Undisclosed"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Amino Acid","year":"2010","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Asembia","sponsor":"Emmaus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Amino Acid","year":"2021","type":"Agreement","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Asembia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Asembia \/ Emmaus Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Asembia \/ Emmaus Life Sciences"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Partner International","sponsor":"Emmaus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Amino Acid","year":"2020","type":"Licensing Agreement","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Partner International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Partner International \/ Emmaus Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Partner International \/ Emmaus Life Sciences"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Amino Acid","year":"2024","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANI Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eastern Regional Medical Center","sponsor":"TSPC America, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TRINIDAD AND TOBAGO","productType":"Amino Acid","year":"2014","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Neurology","graph2":"Phase I","graph3":"Eastern Regional Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eastern Regional Medical Center \/ TSPC America, Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Eastern Regional Medical Center \/ TSPC America, Inc."}]
Find Clinical Drug Pipeline Developments & Deals for Levoglutamide
Details :
Glutamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.
Details :
Glutamine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Irritable Bowel Syndrome.
Details :
ANI’s L-Glutamine Oral Powder is the the first AA-rated generic version of the reference listed drug (RLD) Endari indicated to reduce the acute complications of sickle cell disease.
Details :
Endari (L-glutamine), an amino acid, is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
Details :
Endari (L-glutamine), is approved in the U.S. and several Gulf Cooperation Council countries to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
Details :
Endari is a prescription grade L-glutamine oral powder which is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
Details :
Endari® (L-glutamine), an amino acid, is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
Details :
Compared to baseline, patients had significantly fewer vaso-occlusive crises at 24, 48 and 72 weeks on Endari therapy, as well as fewer hospitalizations (median change from 3.0 to 0; p<0.00001) and fewer days in hospital (median change from 15.0 to 0; p<...
Details :
Endari is a brand-name prescription medication. It’s FDA-approved to reduce the number of sudden complications of sickle cell disease (SCD) and how severe they are. One of the main complications is pain crisis, which is severe pain across the body.
Details :
Endari®, Emmaus' prescription grade L-glutamine oral powder, was approved by the FDA in July 2017 for treating sickle cell disease in adult and pediatric patients five years of age and older.
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
